Group 1 - Dongcheng Pharmaceutical's stock price decreased by 1.03% to 13.49 yuan per share, with a total market capitalization of 11.12 billion yuan as of the report date [1] - The company, established on December 31, 1998, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate, with revenue composition as follows: 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - Xinyi Fund holds a significant position in Dongcheng Pharmaceutical, with its fund "Xinyi Healthcare A" owning 1.2349 million shares, representing 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund has a total scale of 261 million yuan and has achieved a year-to-date return of 22.12%, ranking 4110 out of 8087 in its category [2] Group 3 - The fund manager of Xinyi Healthcare A is Chen Xu, who has been in the position for nearly 5 years, with the fund's total assets amounting to 404 million yuan [3] - During Chen Xu's tenure, the best fund return was -20.35%, while the worst return was -22.24% [3]

Group 1 - Dongcheng Pharmaceutical's stock increased by 5.01%, reaching 15.50 CNY per share, with a trading volume of 201 million CNY and a turnover rate of 1.78%, resulting in a total market capitalization of 12.781 billion CNY [1] - The company, established on December 31, 1998, and listed on May 25, 2012, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate [1] - The revenue composition of Dongcheng Pharmaceutical includes 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - According to data, one fund under Industrial Bank holds Dongcheng Pharmaceutical as a significant investment, with 1.2349 million shares, accounting for 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund, named Industrial Medical Care A (011466), has a current scale of 261 million CNY and has achieved a year-to-date return of 22.76%, ranking 4158 out of 8154 in its category [2] - The fund has a one-year return of 14.98%, ranking 5070 out of 8046, and has experienced a cumulative loss of 20.27% since its inception [2]

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020 [1] - The company's main business involves the research, production, and sales of chemical new drugs and biological new drugs, with 99.97% of revenue coming from pharmaceuticals [1] Fund Holdings - One fund under Industrial Bank, the Industrial Medical Care A (011466), holds 143,000 shares of Zai Jian Pharmaceutical, unchanged from the previous period, representing 4% of the fund's net value [2] - The fund has a total size of 261 million CNY and has achieved a year-to-date return of 24.05% [2] - The fund manager, Chen Xu, has been in position for 4 years and 238 days, with the best and worst fund returns during his tenure being -19.16% and -21.01%, respectively [2]

Core Insights - Tonghua Dongbao Pharmaceutical (300636.SZ) released its Q3 2025 report on October 25, 2025, indicating a total of 63.9184 million A-shares held by three institutional investors, accounting for 15.22% of the company's total share capital [1] - The institutional holding percentage decreased by 1.80 percentage points compared to the previous quarter [1] Institutional Investors - The three institutional investors include: - Fong Lung Industrial Co., Ltd. - Guotai Junaq Securities' special pension product from China Merchants Bank - Jiangxi Chinese Media Blue Ocean International Investment Co., Ltd. [1] - The total institutional holding ratio stands at 15.22% [1] Public Funds - A total of 58 public funds were not disclosed in the current period compared to the previous quarter, including: - Galaxy Medical Mixed A - Industrial Bank Healthcare A - Galaxy Kang Le Stock A - Fuanda Medical Innovation Mixed - Xiangcai Medical Health Mixed A [1]

Core Viewpoint - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. experienced a 6.12% increase, reaching 12.65 CNY per share, with a total market capitalization of 5.546 billion CNY as of September 15 [1] Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [1] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [1] - The revenue composition of the company includes: contrast agents 79.73%, other supplementary products 10.19%, other 6.16%, CMO/CDMO 2.41%, and quinolone series 1.52% [1] Group 2: Fund Holdings - One fund, Xingye Healthcare A (011466), holds a significant position in Sitaili, with 1.8991 million shares, accounting for 4.83% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.14% and a one-year return of 49.23%, ranking 1872 out of 8246 and 3177 out of 8054 in its category, respectively [2] - The fund manager, Chen Xu, has been in position for 4 years and 193 days, with a total fund size of 385 million CNY [2]